BELLUS Health Company Profile (TSE:BLU)

About BELLUS Health (TSE:BLU)

BELLUS Health logoBELLUS Health Inc. is a drug development company focused on rare diseases. The business activities of the Company are development of the Company's core technology platform, amyloid inhibitors, which focus on chemical compounds that could have the potential to inhibit the formation, deposition and toxicity of amyloid fibrils, which are the underlying causes of certain diseases. The Company operates in the business segment of development of drugs for health solutions. It is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. Its pipeline of rare disease projects includes KIACTA in Phase III for Amyloid A (AA) amyloidosis; KIACTA for sarcoidosis; clinical stage Shigamab for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS), and a research-stage project for amyloid light-chain (AL) amyloidosis. It is partnered with global private equity firm Auven Therapeutics for the development of KIACTA.

Industry, Sector and Symbol:
  • Sector: Basic Materials
  • Industry: Industrial Metals & Minerals
  • Sub-Industry: N/A
  • Symbol: TSE:BLU
  • CUSIP: N/A
  • Web:
  • Market Cap: C$29.42 million
  • Outstanding Shares: 66,865,000
Average Prices:
  • 50 Day Moving Avg: C$0.39
  • 200 Day Moving Avg: C$0.37
  • 52 Week Range: C$0.21 - C$0.55
  • Trailing P/E Ratio: 110.00
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $767,000.00
  • Price / Sales: 38.36
  • Book Value: C$0.16 per share
  • Price / Book: 2.75
  • Net Margins: 651.22%
  • Return on Equity: 9.83%
  • Return on Assets: 8.85%
  • Average Volume: 60,997 shs.
  • Short Ratio: 0.04

Frequently Asked Questions for BELLUS Health (TSE:BLU)

What is BELLUS Health's stock symbol?

BELLUS Health trades on the Tornton Stock Exchange (TSX) under the ticker symbol "BLU."

How were BELLUS Health's earnings last quarter?

BELLUS Health Inc (TSE:BLU) released its earnings results on Wednesday, August, 13th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.02). The business earned $0.42 million during the quarter, compared to the consensus estimate of $1 million. BELLUS Health had a return on equity of 9.83% and a net margin of 651.22%. View BELLUS Health's Earnings History.

When will BELLUS Health make its next earnings announcement?

BELLUS Health is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for BELLUS Health.

Who are some of BELLUS Health's key competitors?

How do I buy BELLUS Health stock?

Shares of BELLUS Health and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is BELLUS Health's stock price today?

One share of BELLUS Health stock can currently be purchased for approximately C$0.44.

MarketBeat Community Rating for BELLUS Health (TSE BLU)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  30 (Vote Outperform)
Underperform Votes:  32 (Vote Underperform)
Total Votes:  62
MarketBeat's community ratings are surveys of what our community members think about BELLUS Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BELLUS Health (TSE:BLU) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: N/A
Consensus Price Target History for BELLUS Health (TSE:BLU)
Price Target History for BELLUS Health (TSE:BLU)
Analysts' Ratings History for BELLUS Health (TSE:BLU)
DateFirmActionRatingPrice TargetDetails
3/1/2017Bloom BurtonReiterated RatingBuyView Rating Details
6/20/2016MackieDowngradeSpeculative Buy -> SellView Rating Details
6/20/2016CormarkDowngradeTop Pick -> ReduceView Rating Details
(Data available from 10/19/2015 forward)


Earnings History for BELLUS Health (TSE:BLU)
Earnings by Quarter for BELLUS Health (TSE:BLU)
Earnings History by Quarter for BELLUS Health (TSE BLU)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/13/2014C($0.02)C($0.02)C$1.00 millionC$0.42 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for BELLUS Health (TSE:BLU)
Current Year EPS Consensus Estimate: $-0.03 EPS


Dividend History for BELLUS Health (TSE:BLU)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for BELLUS Health (TSE:BLU)
Insider Trades by Quarter for BELLUS Health (TSE:BLU)
Insider Trades by Quarter for BELLUS Health (TSE:BLU)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017Pierre LarochelleDirectorBuy275,000C$0.36C$99,000.00
7/14/2017Roberto BelliniDirectorBuy225,000C$0.35C$78,750.00
7/20/2015Roberto BelliniDirectorBuy100,000C$1.10C$110,350.00
1/16/2015Francesco BelliniDirectorBuy5,000C$1.03C$5,150.00
(Data available from 1/1/2013 forward)


Headline Trends for BELLUS Health (TSE:BLU)
Latest Headlines for BELLUS Health (TSE:BLU)
DateHeadline logoBELLUS Health Inc (BLU) Director Pierre Larochelle Buys 275,000 Shares - October 3 at 11:16 PM logoBELLUS Health Appoints Dr. Clarissa Desjardins to its Board of Directors - October 2 at 12:59 PM logoBELLUS Health (BLUSF) Updates On BLU-5937 & Chronic Cough Key Opinion Leader Event - Slideshow - September 21 at 4:23 PM logoBELLUS Health Chronic Cough Webcast Taking Place Today - September 20 at 5:22 PM logoBRIEF-Bellus Health's BLU-5937 reduces cough without taste disturbance in two preclinical models - September 18 at 4:57 PM logoBELLUS Health's Blu-5937 Significantly Reduces Cough Without Taste Disturbance in Two Preclinical Models - September 18 at 4:57 PM logoReport Coverage on Healthcare Stocks, BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics - September 14 at 5:15 PM logoBELLUS Health to host webcast on chronic cough and treatment approach on September 20, 2017 - September 6 at 4:38 PM logoBELLUS Health, Inc. :BLU-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 15, 2017 - August 15 at 5:27 PM logoBELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2017 - August 9 at 4:48 PM logoResearch Initiated on Healthcare Stocks, BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics - August 7 at 5:08 PM logoBELLUS Health, Inc. :BLU-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 4, 2017 - August 4 at 9:57 PM logoBELLUS Health Inc (BLU) Set to Announce Quarterly Earnings on Tuesday - August 1 at 7:31 AM logoRoberto Bellini Buys 225,000 Shares of BELLUS Health Inc (TSE:BLU) Stock - July 18 at 4:18 PM logoBELLUS Health Inc. (BLU.TO) - July 9 at 4:29 PM logoBELLUS Health announces closing of the sale of its equity interest in FB Health for total consideration up to CA$2.5M - July 3 at 4:39 PM logoActive Wall Street: Research Reports Initiated on Healthcare Stocks BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics - June 3 at 5:04 AM logoBellus posts 1Q profit - May 10 at 5:20 AM logoIIROC Trading Halt - BLU - March 1 at 8:49 AM logoCanadian Stocks Are Rising As Brexit Looks Unlikely -- Canadian Commentary - June 22 at 8:38 AM logoSavaria, Premium at 52-Week Highs - May 5 at 1:43 PM logoStudy Reached 120 Qualifying Events, Top-Line Results Expected in Q2 2016 - January 21 at 10:13 AM



BELLUS Health (BLU) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.